問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Neurology

Linkou Chang Gung Medical Foundation (在職)

Division of Thoracic Surgery

Division of Radiology

Division of General Internal Medicine

Division of Thoracic Medicine

Division of Hematology & Oncology

更新時間：2023-09-19

陳志弘Chen, Chih-Hung
  • Principal Investigator
  • Clinical Trial Experience (year) 22 years 10 個月

Recruiting Trial

105Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

陳志弘

List

186Cases

2020-04-01 - 2028-12-31

Phase I/II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2006-12-01 - 2013-12-31

Phase III

Not yet recruiting

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2005-10-01 - 2008-05-31

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2020-09-01 - 2026-12-31

Phase II

Active
A Multicenter, Open-label, Single-arm, Phase II Pan-Tumor Study in Patients Who Have Participated in Trials to Investigate Efficacy and Safety of ONO-4538 and Are Continuing ONO-4538 Treatment

  • Condition/Disease

    Pan-Tumor

  • Test Drug

    ONO-4538 (Nivolumab)

Participate Sites
7Sites

Not yet recruiting1Sites

Recruiting3Sites

Terminated3Sites

2021-08-01 - 2024-11-01

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting4Sites

Terminated1Sites

2018-06-08 - 2021-01-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2022-05-01 - 2026-01-11

Phase II

Active

  • Condition/Disease

  • Test Drug

Participate Sites
11Sites

Recruiting11Sites

2022-09-03 - 2027-08-09

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-05-01 - 2030-04-30

Phase III

Active
A Global, Multicenter, Randomized, Open?label, Phase 3 Study of Sacituzumab Govitecan Versus Standard of Care (SOC) in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer (ES-SCLC)

  • Condition/Disease

    Extensive-stage small cell lung cancer (ES-SCLC)

  • Test Drug

    sacituzumab govitecan

Participate Sites
9Sites

Recruiting9Sites

2022-04-05 - 2024-07-31

Phase I/II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

1 4 5 6 7 8 19
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB